Hyundai Pharm
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, a… Read more
Hyundai Pharm (004310) - Total Liabilities
Latest total liabilities as of May 2025: ₩85.40 Billion KRW
Based on the latest financial reports, Hyundai Pharm (004310) has total liabilities worth ₩85.40 Billion KRW as of May 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hyundai Pharm - Total Liabilities Trend (2010–2024)
This chart illustrates how Hyundai Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hyundai Pharm Competitors by Total Liabilities
The table below lists competitors of Hyundai Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
XRF Scientific Ltd
AU:XRF
|
Australia | AU$8.67 Million |
|
Zimplats Holdings Limited
PINK:ZMPLF
|
USA | $1.24 Billion |
|
LH Financial Group Public Company Limited
BK:LHFG
|
Thailand | ฿356.09 Billion |
|
Datalogic S.p.A
OTCGREY:DLGCF
|
USA | $289.41 Million |
|
Acumen Pharmaceuticals Inc
NASDAQ:ABOS
|
USA | $49.05 Million |
|
GKW Limited
NSE:GKWLIMITED
|
India | ₹6.13 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Hyundai Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hyundai Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hyundai Pharm (2010–2024)
The table below shows the annual total liabilities of Hyundai Pharm from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-11-30 | ₩77.32 Billion | +10.51% |
| 2023-11-30 | ₩69.97 Billion | -26.04% |
| 2022-11-30 | ₩94.60 Billion | +22.45% |
| 2021-11-30 | ₩77.26 Billion | +14.69% |
| 2020-11-30 | ₩67.36 Billion | +16.35% |
| 2019-11-30 | ₩57.89 Billion | +11.77% |
| 2018-11-30 | ₩51.80 Billion | -8.35% |
| 2017-11-30 | ₩56.52 Billion | +11.99% |
| 2016-11-30 | ₩50.47 Billion | +19.61% |
| 2013-11-30 | ₩42.19 Billion | -15.98% |
| 2012-11-30 | ₩50.22 Billion | -4.59% |
| 2011-11-30 | ₩52.63 Billion | +36.79% |
| 2010-11-30 | ₩38.48 Billion | -- |